Establishment Labs Holdings ( (ESTA) ) has released its Q2 earnings. Here is a breakdown of the information Establishment Labs Holdings presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Establishment Labs Holdings Inc. is a global medical technology company focused on enhancing women’s health and wellness, particularly in breast aesthetics and reconstruction, through innovative scientific and technological solutions.
In its second quarter of 2025, Establishment Labs reported a significant increase in worldwide revenue, reaching $51.3 million, marking a 16.3% rise from the previous year. The company also revised its 2025 revenue guidance upwards, anticipating a growth of 25% to 28%.
Key financial metrics from the quarter include a gross margin improvement to 68.8% and a reduction in cash use to $14.5 million. Despite a net loss of $16.6 million, the company saw a decrease in its adjusted EBITDA loss compared to the first quarter, reflecting better operational efficiencies.
Looking ahead, Establishment Labs remains optimistic about its growth prospects, driven by increased surgeon utilization and the expansion of its minimally invasive product portfolio. The company aims to achieve positive EBITDA in 2025 and become cash flow positive by 2026.